EP4023224A4 - PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF SOLID CANCER CONTAINING A DERIVATIVE OF EPIDITHIIODIOXOPIPERAZINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF SOLID CANCER CONTAINING A DERIVATIVE OF EPIDITHIIODIOXOPIPERAZINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF Download PDF

Info

Publication number: EP4023224A4
Authority: EP; European Patent Office
Prior art keywords: epidithiiodioxopiperazine; derivative; prevention; treatment; pharmaceutically acceptable
Prior art date: 2019-08-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP20856251.2A

Other languages

German (de)

French (fr)

Other versions

EP4023224A1 (en

Inventor

Sang Won Kang

Eun Kyung Lee

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vasthera Co Ltd

Original Assignee

Vasthera Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-08-28

Filing date

2020-08-25

Publication date

2023-05-03

2020-08-25 Application filed by Vasthera Co Ltd filed Critical Vasthera Co Ltd

2022-07-06 Publication of EP4023224A1 publication Critical patent/EP4023224A1/en

2023-05-03 Publication of EP4023224A4 publication Critical patent/EP4023224A4/en

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP20856251.2A 2019-08-28 2020-08-25 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF SOLID CANCER CONTAINING A DERIVATIVE OF EPIDITHIIODIOXOPIPERAZINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF Pending EP4023224A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20190105964		2019-08-28
PCT/KR2020/011346 WO2021040389A1 (en)	2019-08-28	2020-08-25	Pharmaceutical composition for preventing or treating solid cancer, containing epidithiodioxopiperazine derivative or pharmaceutically acceptable salts thereof

Publications (2)

Publication Number	Publication Date
EP4023224A1 EP4023224A1 (en)	2022-07-06
EP4023224A4 true EP4023224A4 (en)	2023-05-03

Family

ID=74683582

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP20856251.2A Pending EP4023224A4 (en)	2019-08-28	2020-08-25	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF SOLID CANCER CONTAINING A DERIVATIVE OF EPIDITHIIODIOXOPIPERAZINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

Country Status (6)

Country	Link
US (2)	US20220323453A1 (en)
EP (1)	EP4023224A4 (en)
JP (1)	JP2022545732A (en)
KR (1)	KR102599052B1 (en)
CN (1)	CN114641294B (en)
WO (1)	WO2021040389A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993017715A1 (en) *	1992-03-05	1993-09-16	Board Of Regents, The University Of Texas System	Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
CA2252663A1 (en) *	1998-11-03	2000-05-03	Jon C. Clardy	Antineoplastic epidithiapiperazinediones
WO2002026744A1 (en) *	2000-09-27	2002-04-04	Kyowa Hakko Kogyo Co., Ltd.	Mpc1001 derivatives
WO2006066775A1 (en) *	2004-12-23	2006-06-29	Cell Therapeutics Europe S.R.L.	Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions
WO2006135949A2 (en) *	2005-06-21	2006-12-28	Medizinische Universität Wien	Tumour treatment with gliotoxin derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012161799A1 (en) *	2011-02-24	2012-11-29	Georgia Health Sciences University Research Institute, Inc	Epidithiodioxopiperazines and uses thereof in treating cancer
CN102924446B (en) *	2011-08-11	2015-08-26	上海吉铠医药科技有限公司	PIM kinase inhibitor and preparation method thereof and the application in pharmacy
US9765090B2 (en) *	2011-11-25	2017-09-19	Ewha University-Industry Collaboration Foundation	Epidithiodioxopiperazine compound or its derivatives, and the use thereof
KR101472636B1 (en) *	2011-11-25	2014-12-16	이화여자대학교 산학협력단	Pharmaceutical composition for preventing or treating restenosis comprising epidithiodioxopiperazine compound or its derivative； or pharmaceutically acceptable salt thereof
JP6309523B2 (en) *	2012-08-29	2018-04-11	ユニヴァーシティーオブサザンカリフォルニア	Compositions and methods for inhibiting the activity of hypoxia-inducible transcription factor complexes and their use for the treatment of tumors
DK2958926T5 (en) *	2013-05-24	2024-06-10	Vasthera Co Ltd	Epidithiodioxopiperazine compound or derivatives thereof and use thereof
KR102034243B1 (en) *	2016-07-05	2019-10-21	바스테라 주식회사	Pharmaceutical composition for preventing or treating pulmonary arterial hypertension comprising epidithiodioxopiperazine compound or its derivatives, or pharmaceutically acceptable salts thereof
CN109721601B (en) *	2017-10-27	2022-09-16	中国医学科学院药物研究所	Preparation and medical use of a class of tetrahydrocarboline-tetrahydroisoquinoline compounds

2020
- 2020-08-25 KR KR1020200107435A patent/KR102599052B1/en active Active
- 2020-08-25 WO PCT/KR2020/011346 patent/WO2021040389A1/en not_active Ceased
- 2020-08-25 EP EP20856251.2A patent/EP4023224A4/en active Pending
- 2020-08-25 CN CN202080076187.7A patent/CN114641294B/en active Active
- 2020-08-25 US US17/639,295 patent/US20220323453A1/en active Pending
- 2020-08-25 JP JP2022513352A patent/JP2022545732A/en active Pending
2025
- 2025-07-15 US US19/269,344 patent/US20250345343A1/en active Pending

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993017715A1 (en) *	1992-03-05	1993-09-16	Board Of Regents, The University Of Texas System	Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
CA2252663A1 (en) *	1998-11-03	2000-05-03	Jon C. Clardy	Antineoplastic epidithiapiperazinediones
WO2002026744A1 (en) *	2000-09-27	2002-04-04	Kyowa Hakko Kogyo Co., Ltd.	Mpc1001 derivatives
WO2006066775A1 (en) *	2004-12-23	2006-06-29	Cell Therapeutics Europe S.R.L.	Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions
WO2006135949A2 (en) *	2005-06-21	2006-12-28	Medizinische Universität Wien	Tumour treatment with gliotoxin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021040389A1 *

Also Published As

Publication number	Publication date
JP2022545732A (en)	2022-10-28
US20220323453A1 (en)	2022-10-13
CN114641294B (en)	2024-09-13
WO2021040389A1 (en)	2021-03-04
KR102599052B1 (en)	2023-11-07
US20250345343A1 (en)	2025-11-13
KR20210027133A (en)	2021-03-10
CN114641294A (en)	2022-06-17
EP4023224A1 (en)	2022-07-06

Similar Documents

Publication	Publication Date	Title
EP4356975A3 (en)	2024-07-24	Erbb/btk inhibitors
EP4218754A3 (en)	2023-08-16	Methods of treatment for cystic fibrosis
GB201907616D0 (en)	2019-07-10	Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
MX2022010748A (en)	2022-09-23	Methods of treating apol-1 dependent focal segmental glomerulosclerosis.
ATE449081T1 (en)	2009-12-15	FLUORALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES
EP3607952A4 (en)	2020-04-15	USE OF CARRIMYCIN AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND / OR PREVENTION OF TUMORS
BR112021022843A2 (en)	2022-03-03	Compound for the treatment of gout or hyperuricemia
PH12022550790A1 (en)	2023-07-31	Oral complement factor d inhibitors
MX2025005474A (en)	2025-06-02	Pharmaceutical drug containing heterocyclidene acetamide derivative
PH12020551772A1 (en)	2021-07-12	Oxo-substituted compound
AR119159A1 (en)	2021-12-01	ANGIOEDEMA TREATMENTS
MA43876B1 (en)	2019-04-30	Pharmaceutical compositions and their uses against lysosomal storage diseases
TN2022000095A1 (en)	2023-10-09	Oral complement factor d inhibitors
PT1206444E (en)	2004-04-30	COMPOUNDS THAT INHIBIT TRIPTASE ACTIVITY
EP3650029A4 (en)	2021-05-05	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY, CONTAINING AN ADENOSINE DERIVATIVE
EP4023224A4 (en)	2023-05-03	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF SOLID CANCER CONTAINING A DERIVATIVE OF EPIDITHIIODIOXOPIPERAZINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
EP3603647A4 (en)	2021-01-06	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF GLAUCOMA, CONTAINING AN ADENOSINE DERIVATIVE
IL287392A (en)	2021-12-01	Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
MA62176B1 (en)	2025-10-31	PHARMACEUTICAL COMPOSITION CONTAINING ACETOMINOPHENE AND IBUPROFEN
MX2021001349A (en)	2021-04-13	A new medical treatment for pathologic inflammation.
DE69626544D1 (en)	2003-04-10	DRUG SUBSTANCES
MA71514A1 (en)	2025-08-29	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF A PEPTIC ULCER ASSOCIATED WITH A MEDICAMENT CONTAINING ZASTAPRAZAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
EP3459548A4 (en)	2019-05-22	PHARMACEUTICAL COMPOSITION CONTAINING KERATIN 8 PHOSPHORYLATION INHIBITOR FOR THE PREVENTION OR TREATMENT OF MACULAR DEGENERATION, AND METHOD OF SCREENING A MEDICAMENT AGAINST MACULAR DEGENERATION
EP3804708A4 (en)	2022-03-16	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALLODYNIA CAUSED BY ANTICANCER DRUGS
EP3932398A4 (en)	2022-11-30	PHARMACEUTICAL COMPOSITION OF A SINGLE DOSE DOSAGE FORM FOR THE TREATMENT OR PREVENTION OF HYPERTENSION AND HYPERLIPIDEMIA

Legal Events

Date	Code	Title	Description
2021-03-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2022-06-03	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-06-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2022-07-06	17P	Request for examination filed	Effective date: 20220323
2022-07-06	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-12-07	DAV	Request for validation of the european patent (deleted)
2022-12-07	DAX	Request for extension of the european patent (deleted)
2023-05-03	A4	Supplementary search report drawn up and despatched	Effective date: 20230331
2023-05-03	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/00 20060101ALI20230327BHEP Ipc: A61K 31/549 20060101ALI20230327BHEP Ipc: A61K 31/548 20060101AFI20230327BHEP
2024-06-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2024-07-10	17Q	First examination report despatched	Effective date: 20240606
2025-11-09	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2025-11-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2025-12-10	INTG	Intention to grant announced	Effective date: 20251110